Neuspera Medical is developing implantable neuromodulation devices intended to improve the lives of patients battling chronic illnesses. The company is advancing a discreet, minimally invasive, ultra-miniaturized implant designed to provide patients personal control and relief from urinary urge incontinence (UUI), a symptom of overactive bladder (OAB). The Neuspera System includes an ultra-miniaturized pulse generator attached to an electrode array. Led by CEO Steffen Hovard, the company emphasizes minimally invasive, patient-controlled therapy. Neuspera recently raised $23M in a Series D financing and intends to use the funds to further enhance growth through expected U.S. Food and Drug Association (FDA) premarket approval (PMA) of its system. Neuspera Medical is a San Jose, Calif.-based, clinical-stage, venture-backed medical device company that engineers miniaturized implantable neuromodulation technologies. The company leverages both exclusively licensed and proprietary power transfer techniques to build its platform. Its lead indication is Urinary Urgency Incontinence, a symptom of overactive bladder, and it describes its products as part of bioelectronic medicines. Neuspera intends to use the Series C proceeds to conduct the SANS-UUI pivotal clinical study. The company is led by Milton M. Morris, Ph.D., President & CEO. It closed a $65M Series C equity financing in July 2021. Neuspera Medical is a clinical-stage neuromodulation company based in San Jose, CA. The company engineers miniaturized implantable neuromodulation technologies using exclusively licensed and proprietary power transfer techniques. Its technology platform, described as bioelectronics medicines, aims to provide patients and physicians less invasive, more adaptable, and potentially earlier treatment options. Neuspera is led by Milton M. Morris, Ph.D., President & CEO. The company intends to use the financing to advance its clinical programs for its implantable neuromodulation technology platform. Neuspera focuses on product development and regulatory programs tied to milestone-driven funding tranches. Neuspera Medical is a clinical-stage medical device company based in San Jose, California that develops miniaturized implantable neuromodulation technologies. It engineers hermetically sealed implantable modules using exclusively licensed and proprietary power transfer techniques. The company describes its modules as more than 100 times smaller than other neuromodulation devices and says they may reduce implant procedure complexity, patient complication, and post-surgical pain. Neuspera positions its products within a bioelectronics medicines technology platform. Led by President & CEO Milton M. Morris, Ph.D., the company focuses on advancing product development and clinical programs. It held the initial closing of a $26M Series B equity financing to support those efforts.

Total raised

$126M

Funding rounds

4

Latest round

Series D

Latest activity

Jul 2024